2019
Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy
Siebel S, Galderisi A, Patel NS, Carria LR, Tamborlane WV, Sherr JL. Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy. Diabetes Technology & Therapeutics 2019, 21: 101-104. PMID: 30688521, PMCID: PMC6434586, DOI: 10.1089/dia.2018.0356.Peer-Reviewed Original ResearchConceptsType 1 diabetesFree fatty acidsSGLT2i useAspart insulinSGLT2 inhibitor therapyPlasma glucose levelsSodium-glucose cotransporterCanagliflozin treatmentEuglycemic DKARescue therapyBasal insulinInhibitor therapyRate of ketogenesisRescue treatmentBlunted increaseSubcutaneous injectionGlucose levelsTreatment studiesNormal increaseInsulinDiabetesTherapyKetogenesisFatty acidsTreatment
2012
Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device
Cengiz E, Weinzimer SA, Sherr JL, Tichy E, Martin M, Carria L, Steffen A, Tamborlane WV. Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. Pediatric Diabetes 2012, 14: 168-173. PMID: 23107353, PMCID: PMC3572265, DOI: 10.1111/pedi.12001.Peer-Reviewed Original ResearchConceptsPlasma insulin levelsInsulin actionInsulin levelsAspart insulinRapid-acting insulin analoguesPhysiologic insulin actionClosed-loop insulin deliveryPostprandial glucose excursionsEuglycemic clamp techniqueIp activationTime-action profileType 1 diabetesWarming devicesEuglycemic clamp procedureBolus doseGlucose excursionsPharmacodynamic profileClamp procedurePeak actionInfusion siteBlood flowInsulin analoguesClamp techniqueInsulin absorptionInsulin bolus